Last reviewed · How we verify

Ramucirumab (IMC-1211B) DP

Eli Lilly and Company · Phase 3 active Biologic

Ramucirumab (IMC-1211B) DP is a VEGFR2 inhibitor (monoclonal antibody) Biologic drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Metastatic non-small cell lung cancer (in combination with docetaxel), Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy), Metastatic colorectal cancer (in combination with FOLFIRI). Also known as: LY3009806, IMC-1211B.

Ramucirumab is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenesis and vascular growth.

Ramucirumab is a monoclonal antibody developed by Eli Lilly for the treatment of metastatic gastric adenocarcinoma. It targets VEGFR-2 to inhibit angiogenesis. Despite no FDA label, it has completed a Phase 3 trial showing promise in combination with paclitaxel.

At a glance

Generic nameRamucirumab (IMC-1211B) DP
Also known asLY3009806, IMC-1211B
SponsorEli Lilly and Company
Drug classVEGFR2 inhibitor (monoclonal antibody)
TargetVEGFR2 (Vascular Endothelial Growth Factor Receptor 2)
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Ramucirumab binds to VEGFR2 on endothelial cells, preventing ligand-induced activation and downstream signaling that promotes new blood vessel formation. By inhibiting angiogenesis, the drug reduces blood supply to tumors, limiting their growth and metastatic potential. It is often used in combination with chemotherapy to enhance anti-tumor efficacy.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ramucirumab (IMC-1211B) DP

What is Ramucirumab (IMC-1211B) DP?

Ramucirumab (IMC-1211B) DP is a VEGFR2 inhibitor (monoclonal antibody) drug developed by Eli Lilly and Company, indicated for Metastatic non-small cell lung cancer (in combination with docetaxel), Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy), Metastatic colorectal cancer (in combination with FOLFIRI).

How does Ramucirumab (IMC-1211B) DP work?

Ramucirumab is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenesis and vascular growth.

What is Ramucirumab (IMC-1211B) DP used for?

Ramucirumab (IMC-1211B) DP is indicated for Metastatic non-small cell lung cancer (in combination with docetaxel), Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy), Metastatic colorectal cancer (in combination with FOLFIRI), Hepatocellular carcinoma (in combination with atezolizumab).

Who makes Ramucirumab (IMC-1211B) DP?

Ramucirumab (IMC-1211B) DP is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is Ramucirumab (IMC-1211B) DP also known as anything else?

Ramucirumab (IMC-1211B) DP is also known as LY3009806, IMC-1211B.

What drug class is Ramucirumab (IMC-1211B) DP in?

Ramucirumab (IMC-1211B) DP belongs to the VEGFR2 inhibitor (monoclonal antibody) class. See all VEGFR2 inhibitor (monoclonal antibody) drugs at /class/vegfr2-inhibitor-monoclonal-antibody.

What development phase is Ramucirumab (IMC-1211B) DP in?

Ramucirumab (IMC-1211B) DP is in Phase 3.

What are the side effects of Ramucirumab (IMC-1211B) DP?

Common side effects of Ramucirumab (IMC-1211B) DP include Hypertension, Diarrhea, Fatigue, Nausea, Headache, Bleeding events.

What does Ramucirumab (IMC-1211B) DP target?

Ramucirumab (IMC-1211B) DP targets VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and is a VEGFR2 inhibitor (monoclonal antibody).

Related